Physician

James E Splichal, M.D.

According to 2025 Medicare claims, James Splichal, M.D. (NPI: 1588619142) practices hematology/oncology in the Atlanta-Sandy Springs-Roswell, GA market, with the plurality of this provider's patient population coming from Walton, GA. This provider's primary affiliated billing organization is UNIVERSITY CANCER & BLOOD CENTER LLC (NPI: 1346343761; TIN: 20-1842623) and primary practice location at 30607-1465.

Splichal's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 1,021 traditional Medicare patients, billed 161,274 HCPCS/CPT codes, and received $4,112,849 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,130 prescription claims across 491 beneficiaries totaling $6,148,409 in drug costs, led by Xtandi (Enzalutamide). DME data shows 49 claims. Open Payments data shows 151 records totaling $152,292. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,133,722 to $4,112,849. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $3,160,445 to $6,148,409. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $9,170 and ending at $12,956.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,069	175,726	$2,133,722
2016	1,053	221,018	$2,414,290
2017	1,086	185,023	$2,704,114
2018	1,060	247,272	$3,835,693
2019	1,017	234,524	$3,907,666
2020	1,037	216,367	$4,040,260
2021	1,113	228,118	$3,826,510
2022	1,002	197,985	$4,274,070
2023	964	194,587	$4,177,667
2024	1,021	161,274	$4,112,849

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	521	4,549	$3,160,445
2016	467	3,712	$2,597,409
2017	453	3,234	$3,023,978
2018	451	3,203	$4,186,674
2019	429	3,198	$4,327,023
2020	426	3,201	$4,422,089
2021	452	3,045	$4,764,656
2022	480	3,728	$6,740,911
2023	476	3,523	$7,275,565
2024	491	3,130	$6,148,409

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	46	300	$82,784
2016	52	296	$50,121
2017	73	235	$32,301
2018	12	123	$12,439
2019	40	242	$21,959
2020	30	112	$6,526
2021	N/R	105	$5,089
2022	N/R	171	$6,689
2023	N/R	130	$14,335
2024	N/R	49	$2,439

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	670	1,685	$90
36415	Insertion of needle into vein for collection of blood sample	624	1,860	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	588	1,801	$8
83615	Lactate dehydrogenase (enzyme) level	299	473	$6
84550	Uric acid level, blood	297	473	$4

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Xtandi	Enzalutamide	55	1,650	$761,212
Cabometyx	Cabozantinib S-Malate	30	900	$751,397
Revlimid	Lenalidomide	23	637	$386,534
Procrit	Epoetin Alfa	265	5,593	$353,767
Tagrisso	Osimertinib Mesylate	19	570	$305,876

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E0260	Hospital bed, semi-electric (head and foot adjustment), with any type side rails, with mattress	Y	N/R	21	$1,549
E0656	Segmental pneumatic appliance for use with pneumatic compressor, trunk	Y	N/R	14	$649
E0181	Powered pressure reducing mattress overlay/pad, alternating, with pump, includes heavy duty	Y	N/R	14	$241

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	149	$3,727	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	2	$148,565	E.R. Squibb & Sons, L.L.C.
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for James E. Splichal, M.D.?

Tedicare shows public-source Medicare data for James E. Splichal, M.D. (NPI 1588619142), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does James E. Splichal, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to James E. Splichal, M.D.?

James E. Splichal, M.D. is linked to UNIVERSITY CANCER & BLOOD CENTER LLC (billing NPI 1346343761) in the available physician profile data.

Does James E. Splichal, M.D. have Open Payments data?

James E. Splichal, M.D. has 151 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.